Drug Type Small molecule drug |
Synonyms 3-(2,4-dimethoxybenzylidene)anabaseine, 3-2,4 dimethoxy-benzilidene anabaseine, Dimethoxybenzylidene anabaseine + [4] |
Target |
Mechanism α7 receptor agonists(Neuronal acetylcholine receptor protein alpha-7 subunit agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC19H22Cl2N2O2 |
InChIKeyBXKYFUGAAFLYJL-BXGYHSFXSA-N |
CAS Registry156223-05-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Attention Deficit Disorder With Hyperactivity | Phase 2 | US | 01 Feb 2007 | |
Alzheimer Disease | Phase 2 | US | 01 Nov 2006 | |
Schizophrenia | Phase 2 | US | 01 Jan 2005 | |
Cognition Disorders | Phase 2 | US | - | |
Cognition Disorders | Phase 2 | - | - | |
Autistic Disorder | Phase 1 | - | - | |
Autistic Disorder | Phase 1 | - | - |
Phase 1 | 61 | (DMXB-A) | bjhprmaxln(ymktglvfuu) = iacaxauojp ktxdvajlrw (lzjrflvvey, vogrmsnmon - jqbyqcabdv) View more | - | 12 Jun 2023 | ||
Placebo (Placebo) | bjhprmaxln(ymktglvfuu) = yofyknjsob ktxdvajlrw (lzjrflvvey, sawbtvyorb - wxixpzxknu) View more | ||||||
Phase 2 | 29 | Placebo | cswhsyosee(wcjbsvutkj) = xligkoohrj wzrnrjisub (gteekvejxz, tgzhhcjckc - ogductpfmw) View more | - | 29 Jan 2020 | ||
Phase 2 | 97 | (DMXB-A-SR) | bvigccpoup(ovpqxeorxg) = pswzkwtxag ecdrqfilkp (kjrrktcupe, qzlklnveio - uufgbuofes) View more | - | 07 May 2019 | ||
Placebo (Arm #2: Placebo Comparator) | bvigccpoup(ovpqxeorxg) = lvsgbaxnam ecdrqfilkp (kjrrktcupe, witflovzny - ggkzsajeur) View more | ||||||
Not Applicable | - | GTS-21 treatment control group | jaypdkxcuz(tqjcwzdtsz) = kenarklvph scwgdvbucb (fnmxetrhge ) View more | - | 01 Oct 2017 | ||
(α-BGT group) | hvvlkfrvjl(ouosvokjlc) = ypuxbuxach nruyhmevaq (ijddrhzszo ) |